GlassScriptPhysician profile
Brett W Mercer
NPI 1427416114
$18,844.84
in general payments reported to CMS, 2019-2025
62 companies · $5,277 in 2025
The $5,277 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $634 · 2021: $2,574 · 2022: $2,112 · 2023: $2,647 · 2024: $5,244 · 2025: $5,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $2,992 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,141.65 |
| Travel and Lodging | $2,991.83 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,085.91 | 2023-2025 | Infinity |
| Ucb, INC. | $1,812.98 | 2020-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $1,619.93 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,160.80 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Boston Scientific Corporation | $1,154.62 | 2025 | General - Therapies, Vercise, General - Pain Management |
| Medtronic, INC. | $948.71 | 2025 | Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $917.82 | 2020-2025 | Ultomiris, Soliris |
| Eisai INC. | $817.80 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $501.68 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $367.70 | 2020-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $345.24 | 2020-2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $335.87 | 2023-2024 | Onpattro, Amvuttra |
| Amneal Pharmaceuticals LLC | $319.24 | 2019-2024 | Rytary, Crexont |
| Neurelis, INC. | $312.28 | 2020-2025 | Valtoco |
| Horizon Therapeutics Plc | $305.27 | 2021-2023 | Uplizna |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Mercer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.